GlassScriptPhysician profile
Katie E Gardner
NPI 1336521194
$5,096.54
in general payments reported to CMS, 2019-2025
29 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.76 · 2021: $45.87 · 2022: $3,425 · 2023: $698 · 2024: $616 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,016.99 | 2022 | |
| Glaxosmithkline, LLC. | $473.40 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.89 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Atricure, INC. | $182.62 | 2023 | |
| Merck Sharp & Dohme LLC | $140.66 | 2022-2024 | Zerbaxa |
| Astrazeneca Pharmaceuticals LP | $118.04 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Baxter Healthcare | $96.91 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Grifols USA, LLC | $79.66 | 2022-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $76.86 | 2024-2025 | |
| Mylan Specialty L.P. | $60.34 | 2022-2024 | Yupelri |
| Olympus America INC. | $58.08 | 2024 | Spiration Valve System |
| United Therapeutics Corporation | $48.74 | 2022-2023 | Tyvaso |
| Mallinckrodt Hospital Products INC. | $47.08 | 2022-2023 | Acthar |
| Actelion Pharmaceuticals US, INC. | $45.91 | 2025 | Uptravi, Opsumit, Opsynvi |
| Abbvie INC. | $45.31 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $43.33 | 2021-2023 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $40.97 | 2024-2025 | Dupixent |
| Boston Scientific Corporation | $32.20 | 2024 | |
| Philips North America LLC | $32.14 | 2022-2025 | Vest Therapy Und |
| Inogen, INC. | $31.65 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.26 | 2022-2023 | |
| Sandoz INC. | $28.29 | 2024 | Treprostinil |
| Olympus Corporation of The Americas | $25.76 | 2019 | |
| Vifor Pharma, INC. | $25.26 | 2024 | Zemaira |
| Pulmonx Corporation | $24.46 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Aimmune Therapeutics, INC. | $21.49 | 2024 | |
| Viatris Specialty LLC | $18.54 | 2025 | Yupelri |
| Shionogi INC | $17.28 | 2022 | |
| Pfizer INC. | $16.42 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.